[Federal Register Volume 78, Number 6 (Wednesday, January 9, 2013)] [Notices] [Page 1848] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2013-00226] ======================================================================= ----------------------------------------------------------------------- DEPARTMENT OF DEFENSE Department of the Army Intent To Grant an Exclusive License of a U.S. Government-Owned Invention AGENCY: Department of the Army, DoD. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: In accordance with 35 U.S.C. 209(e), and 37 CFR 404.7(a)(1)(i) and 37 CFR 404.7(b)(1)(i), announcement is made of the intent to grant an exclusive, revocable license to the invention claimed in U.S. Patent No. 6,316,197, entitled ``Method of Diagnosing of Exposure to Toxic Agents by Measuring Distinct Pattern in the Levels of Expression of Specific Genes,'' issued on November 13, 2001, and foreign rights to Cascade Biotherapeutics, Inc., with its principal place of business at 4938 Hampden Lane319, Bethesda, Maryland 20814-2914. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, MD 21702-5012. FOR FURTHER INFORMATION CONTACT: For licensing issues, Dr. Paul Mele, Office of Research & Technology Applications, (301) 619-6664. For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808; both at telefax (301) 619-5034. SUPPLEMENTARY INFORMATION: Anyone wishing to object to grant of this license can file written objections along with supporting evidence, if any, within 15 days from the date of this publication. Written objections are to be filed with the Command Judge Advocate (see ADDRESSES). Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. 2013-00226 Filed 1-8-13; 8:45 am] BILLING CODE 3710-08-P